Proangiogenic or proimmunogenic genomic and transcriptomic signatures in the tumor microenvironment may have predictive value.
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
Patients may find misinformation on websites or social media forums, but doctors can help by recommending reliable sources.
The American College of Sports Medicine reconvened the ACSM Roundtable to update its guidelines for prescribing exercise for patients and survivors of cancers.
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
Palliative care can be effectively introduced along with other treatments, and the combination of care improves patient symptoms and quality of life.
Pretreatment significantly affected health outcomes for patients with metastatic breast cancer.
Women are less likely to be introduced by their professional title and most likely to be introduced by first name.
Mental health disorders may be an adverse effect of head and neck cancer diagnosis, treatment, or treatment morbidities.
FDA analyses find trial-to-trial variation in the analysis of patient reported outcomes, underscoring the need for standardization.
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays.
Multiple postmarketing studies have pointed to percentages of cardiovascular-associated AEs with ibrutinib that are higher than the number outlined in the drug’s PI.
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Findings underscore the limited generalizability of clinical trial results to patients in the real world.
Primary central nervous system lymphoma (PCNSL) is a rare (incidence rate of 0.6 cases per 100,000 person years) non-Hodgkin lymphoma (NHL) found in the brain, spinal cord, and leptomeninges.